Journal article

Relaxin-2 Does Not Ameliorate Nephropathy in an Experimental Model of Type-1 Diabetes

Thomas Bernd Dschietzig, Katharina Krause-Relle, Maud Hennequin, Karoline von Websk, Jan Rahnenfuhrer, Jana Ruppert, Hans Juergen Groena, Franz Paul Armbruster, Ross AD Bathgate, Joerg R Aschenbach, Wolf-Georg Forssmann, Berthold Hocher

KIDNEY & BLOOD PRESSURE RESEARCH | KARGER | Published : 2015

Abstract

BACKGROUND/AIMS: In diabetic nephropathy (DN), the current angiotensin-II-blocking pharmacotherapy is frequently failing. For diabetic cardiomyopathy (DC), there is no specific remedy available. Relaxin-2 (Rlx) - an anti-fibrotic, anti-inflammatory, and vasoprotecting peptide – is a candidate drug for both. METHODS: Low-dose (32 μg/kg/day) and high-dose (320 μg/kg/day) Rlx were tested against vehicle (n = 20 each) and non-diabetic controls (n = 14) for 12 weeks in a model of type-1 diabetes induced in endothelial nitric oxide synthase knock-out (eNOS-KO) mice by intraperitoneal injection of streptozotocin. RESULTS: Diabetic animals showed normal plasma creatinine, markedly increased albuminu..

View full abstract